• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Henry Schein Inc.

    5/12/26 9:00:08 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    DEFA14A 1 d20870ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☑

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    HENRY SCHEIN, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☑

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    EXPLANATORY NOTE

    On April 8, 2026, Henry Schein, Inc. (the “Company”) filed its definitive proxy statement (the “Proxy Statement”) and form of Proxy relating to the solicitation of proxies by the Company in connection with its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The Proxy Statement is available on the Company’s website at https://investor.henryschein.com/financials/annual-reports/default.aspx and is also available on the website maintained by the Securities and Exchange Commission at www.sec.gov. The information included in this filing should be read in conjunction with the Proxy Statement, which should be read in its entirety. This filing supplements certain of the information contained in the Proxy Statement. Except as described herein, this supplement does not modify, amend, supplement, or otherwise affect the Proxy Statement or the accompanying proxy card.

    Re-Election of Directors William K. “Dan” Daniel and Max Lin

    As described in the Proxy Statement, the Company strongly believes that William K. “Dan” Daniel and Max Lin, two of our director nominees, are independent in all respects and are eminently qualified to serve on the Company’s Compensation Committee and Nominating and Governance Committee, respectively, and strongly recommend that shareholders vote “FOR” Mr. Daniel and Mr. Lin, for the following reasons:

     

      •  

    Our Board has determined that Mr. Daniel and Mr. Lin meet all director independence standards under the Nasdaq Listing Rules and Rule 10A-3 under the Securities Exchange Act of 1934.

     

      •  

    Mr. Daniel and Mr. Lin were each added to the Board in connection with the Company’s Strategic Partnership Agreement with KKR, by which KKR invested $250 million in the Company’s common stock. KKR remains the Company’s largest stockholder. Neither Mr. Daniel nor Mr. Lin work directly or indirectly for KKR Capstone (“Capstone”), a consulting company that provided consulting services to the Company in 2025.

     

      •  

    As noted in the Proxy Statement, Mr. Lin will not receive any direct compensation from the engagement of Capstone. Further, KKR reported approximately $19 billion in revenues for the fiscal year ended December 31, 2025. The $2.5 million paid by the Company to Capstone in fiscal 2025 was not material to KKR’s financial results.

     

      •  

    Mr. Daniel is an executive advisor and not an employee of KKR. The Capstone consulting arrangement with the Company has no direct or indirect economic impact on Mr. Daniel’s compensation.

     

      •  

    During his tenure on the Compensation Committee, Mr. Daniel has been directly involved in the design of compensation structures for the Company’s incoming Chief Executive Officer — work that draws on his experience overseeing executive compensation across multiple business segments during his 14 years as Executive Vice President at Danaher Corporation.

     

      •  

    During his tenure on the Nominating and Governance Committee, Mr. Lin was directly involved in the evaluation of candidates during the CEO search process. His experience evaluating executive talent across large, complex healthcare and distribution businesses provided meaningful insight in the process that resulted in the appointment of Frederick M. Lowery as CEO.

    Every vote is important. We ask that shareholders consider the information included in this communication and the Proxy Statement in casting their vote.

    Our Board unanimously recommends that shareholders vote “FOR” the election of all director nominees, including Mr. Daniel and Mr. Lin.

    Identification of Shareholder Proposal Proponent In Proposal 4

    The Company hereby discloses the name of the shareholder proponent relating to the shareholder proposal intended to be presented at the Annual Meeting: Proposal 4: Govern by Majority Vote.

    The shareholder proposal was submitted by John Chevedden.

    Mr. Chevedden has represented that he has held the required amount of Company stock for the requisite period under Rule 14a-8 and has notified the Company of his intention to present Proposal 4 at the Annual Meeting.

    We invite shareholders to read the full text of the shareholder proposal and the Company’s statement of opposition on pages 75 and 76 of the Proxy Statement.

    Our Board unanimously recommends that shareholders vote “AGAINST” Proposal 4.


    Engagement of Proxy Solicitor

    Subsequent to filing the Proxy Statement, the Company retained Innisfree M&A Incorporated (“Innisfree”), an independent proxy solicitation firm, to assist in soliciting proxies on the Company’s behalf, which they may conduct by personal interview, mail, telephone, facsimile, email, other electronic channels of communication or otherwise. The Company has agreed to pay Innisfree a fee of $30,000, plus costs and expenses, for these services. In addition, the Company has agreed to indemnify Innisfree and certain related persons against certain liabilities relating to or arising out of Innisfree’s engagement. If stockholders need assistance with casting or changing their vote, they should contact Innisfree, toll free, at 877-456-3513.

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    4/16/2026Neutral
    BTIG Research
    4/15/2026$100.00Buy
    Citigroup
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    More analyst ratings

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Henry Schein

    BTIG Research initiated coverage of Henry Schein with a rating of Neutral

    4/16/26 8:03:48 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Henry Schein with a new price target

    Citigroup initiated coverage of Henry Schein with a rating of Buy and set a new price target of $100.00

    4/15/26 8:08:55 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

    Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution. Across both DSOs and independent practices, the highest-perf

    5/14/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form SD filed by Henry Schein Inc.

    SD - HENRY SCHEIN INC (0001000228) (Filer)

    5/29/26 3:04:28 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    5/22/26 8:00:11 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Henry Schein Inc.

    DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)

    5/12/26 9:00:08 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Murphy Kelly Ann claimed ownership of 34,812 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/28/26 5:01:47 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: Former Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4/A - HENRY SCHEIN INC (0001000228) (Issuer)

    5/26/26 5:16:26 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/22/26 7:03:42 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $691,900 worth of shares (10,000 units at $69.19) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/12/26 4:15:46 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2026 financial results before the stock market opens on Tuesday, May 5, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Frederick M. Lowery, Chief Executive Officer and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the prese

    4/21/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care